{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:05:38Z","timestamp":1792692338991,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research","doi-asserted-by":"publisher","award":["SKLDR-2022-LH-07"],"award-info":[{"award-number":["SKLDR-2022-LH-07"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB0830000"],"award-info":[{"award-number":["XDB0830000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073875"],"award-info":[{"award-number":["82073875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118650","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:54:19Z","timestamp":1770191659000},"page":"118650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel pyrrolo[1,2-b]pyridazin-2(1H)-ones as selective PARP1 inhibitors for cancer therapy"],"prefix":"10.1016","volume":"307","author":[{"given":"Qiaolin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiajuan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-5808","authenticated-orcid":false,"given":"Chunhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118650_bib1","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.2147\/OTT.S139336","article-title":"Current status of poly(ADP-ribose) polymerase inhibitors and future directions","volume":"10","author":"Ohmoto","year":"2017","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118650_bib2","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1016\/S0960-9822(98)70032-6","article-title":"DNA repair: PARP \u2013 another guardian angel?","volume":"8","author":"Jeggo","year":"1998","journal-title":"Curr. Biol."},{"issue":"1-2","key":"10.1016\/j.ejmech.2026.118650_bib3","first-page":"97","article-title":"Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death","volume":"477","author":"Herceg","year":"2001","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ejmech.2026.118650_bib4","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.2741\/2909","article-title":"The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases","volume":"13","author":"Hassa","year":"2008","journal-title":"Front. Biosci."},{"issue":"7381","key":"10.1016\/j.ejmech.2026.118650_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"6082","key":"10.1016\/j.ejmech.2026.118650_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.1216338","article-title":"Structural basis for DNA damage\u2013dependent Poly(ADP-ribosyl)ation by Human PARP-1","volume":"336","author":"Langelier","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118650_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41467-018-03234-8","article-title":"NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains","volume":"9","author":"Langelier","year":"2018","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118650_bib8","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118650_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/jpet.113.210146","article-title":"Rationale for Poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition","volume":"349","author":"Murai","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118650_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Targeted Oncol."},{"issue":"7035","key":"10.1016\/j.ejmech.2026.118650_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.ejmech.2026.118650_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118650_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118650_bib14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118650_bib15","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118650_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40265-017-0752-y","article-title":"Niraparib: first global approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118650_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2159-8290.CD-NB2016-164","article-title":"Rucaparib approved for ovarian cancer","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118650_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon-2019-0689","article-title":"Olaparib for advanced breast cancer","volume":"16","author":"Griguolo","year":"2020","journal-title":"Future Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118650_bib19","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40265-025-02200-1","article-title":"Senaparib: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118650_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/1535-7163.MCT-23-0625","article-title":"The discovery of a potent PARP1 inhibitor senaparib","volume":"24","author":"Cai","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118650_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14737140.2024.2333320","article-title":"Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives","volume":"24","author":"Kim","year":"2024","journal-title":"Expet Rev. Anticancer Ther."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118650_bib22","doi-asserted-by":"crossref","first-page":"16464","DOI":"10.1021\/acs.jmedchem.3c00865","article-title":"Advances in development of selective antitumor inhibitors that target PARP-1","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118650_bib23","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1016\/j.molcel.2024.09.020","article-title":"Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts","volume":"84","author":"Lin","year":"2024","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118650_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cancers12020392","article-title":"Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies","volume":"12","author":"Y\u00e9lamos","year":"2020","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118650_bib25","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118650_bib26","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, A next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118650_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-3-319-91442-8_15","article-title":"Olaparib","volume":"211","author":"Bochum","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118650_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127710","article-title":"Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors","volume":"31","author":"Xiang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118650_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2016.11.010","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials","volume":"386","author":"Yuan","year":"2017","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.ejmech.2026.118650_bib30","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.1021\/acs.jmedchem.3c00821","article-title":"YCH1899, a highly effective Phthalazin-1(2H)-one derivative that overcomes resistance to prior PARP inhibitors","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118650_bib31","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/aps.2017.104","article-title":"Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118650_bib32","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.18632\/oncotarget.3264","article-title":"Dual targeting of microtubule and topoisomerase II by \u03b1-carboline derivative YCH337 for tumor proliferation and growth inhibition","volume":"6","author":"Yi","year":"2015","journal-title":"Oncotarget"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:40:57Z","timestamp":1777398057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["S0223523426000954"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118650","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel pyrrolo[1,2-b]pyridazin-2(1H)-ones as selective PARP1 inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118650"}}